127
Views
2
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Comparison of Outcomes in Patients with Obesity Between Two Administration Routes of Omeprazole After Laparoscopic Sleeve Gastrectomy: An Open-Label Randomized Clinical Trial

ORCID Icon, , , , &
Pages 1569-1576 | Published online: 15 Apr 2021

References

  • CecchiniM, SassiF, LauerJA, et al. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376(9754):1775–1784. doi:10.1016/S0140-6736(10)61514-021074255
  • World obesity federation about obesity. Available from: https://www.worldobesity.org/about/about-obesity. Accessed 327, 2021.
  • NgM, FlemingT, RobinsonM, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–781. doi:10.1016/S0140-6736(14)60460-824880830
  • RebiboL, MarechalV, De LamethI, et al. Compliance with a multidisciplinary team meeting’s decision prior to bariatric surgery protects against major postoperative complications. Surg Obes Relat Dis. 2017;13(9):1537–1543. doi:10.1016/j.soard.2017.05.02628705572
  • Chinese Society for Metabolic & Bariatric Surgery. The guidelines for surgical treatment of obesity and T2D in China. Chin J Pract Surg. 2019;39(4):301–306.
  • HelmioM, VictorzonM, OvaskaJ, et al. Comparison of short-term outcome of laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: a prospective randomized controlled multicenter SLEEVEPASS study with 6-month follow-up. Scand J Surg. 2014;103(3):175–181. doi:10.1177/145749691350998424522349
  • HimpensJ, DapriG, CadiereGB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg. 2006;16(11):1450–1456. doi:10.1381/09608920677886993317132410
  • GibsonSC, Le PagePA, TaylorCJ. Laparoscopic sleeve gastrectomy: review of 500 cases in single surgeon Australian practice. ANZ J Surg. 2015;85(9):673–677. doi:10.1111/ans.1248324354405
  • FurutaT, ShiraiN, SugimotoM, OhashiK, IshizakiT. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181–202. doi:10.1517/phgs.5.2.181.2748315016609
  • WeiM, XiaoY. Study of stability of omeprazole in micro-pump by continuous administration. China Pharm. 2005;16:1884–1885.
  • RichterJE, KahrilasPJ, JohansonJ, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96(3):656–665. doi:10.1111/j.1572-0241.2001.03600.x11280530
  • HanleyMJ, AbernethyDR, GreenblattDJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87. doi:10.2165/11318100-000000000-0000020067334
  • HeX, LiY, YangX, et al. Effects of endoscopic hemostasis in combination with different dose of omeprazole effect in the treatment of elderly peptic ulcer bleeding. Mod Dig Intervention. 2019;24(2):183–185.
  • ChenJ. Clinical efficacy and safety of continuous intravenous infusion of low dosage omeprazole for the treatment of neonatal stress ulcer. Chin J Clin Pharmacol. 2015;31(18):1812–1814.
  • CsendesA, BraghettoI. Changes in the anatomy and physiology of the distal esophagus and stomach after sleeve gastrectomy. J Obes Weight Loss Ther. 2016;6:297. doi:10.4172/2165-7904.1000297
  • ShinJM, SachsG. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528–534. doi:10.1007/s11894-008-0098-419006606
  • NilssonM, JohnsenR, YeW, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003;290(1):66–72. doi:10.1001/jama.290.1.6612837713
  • HimpensJ, DobbeleirJ, PeetersG. Long-term results of laparoscopic sleeve gastrectomy for obesity. Ann Surg. 2010;252(2):319–324. doi:10.1097/SLA.0b013e3181e90b3120622654
  • StenardF, IannelliA. Laparoscopic sleeve gastrectomy and gastroesophageal reflux. World J Gastroenterol. 2015;21(36):10348–10357. doi:10.3748/wjg.v21.i36.1034826420961
  • MinerP Jr., KatzPO, ChenY, SostekM. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616–2620. doi:10.1111/j.1572-0241.2003.08783.x14687806
  • SaccarCL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol. 2009;5(9):1113–1124. doi:10.1517/1742525090312436319606942
  • McKeageK, BlickSKA, CroxtallJD, et al. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs. 2008;68(11):1571–1607. doi:10.2165/00003495-200868110-0000918627213
  • ZahnJD, DeshmukhA, PisanoAP, LiepmannD. Continuous on-chip micropumping for microneedle enhanced drug delivery. Biomed Microdevices. 2004;6(3):183–190. doi:10.1023/B:BMMD.0000042047.83433.9615377827
  • PetersonKA, ThomasKL, HildenK, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci. 2010;55(5):1313–1319. doi:10.1007/s10620-009-0859-419533356
  • MoS. Clinical efficacy and safety evaluation of continuous low-dose micropump infusion of omeprazole in the treatment of stress ulcer in neonates. Chin Foreign Med Res. 2018;16(17):28–30.
  • DuanW, TanY, PengZ. Efficacy of continuous intravenous infusion of low-dose omeprazole in the treatment of neonatal stress ulcer. J Ped Pharm. 2013;19(1):12–14.
  • LiuY, LiM, ZhangS, et al. North China bariatric & metabolic surgery clinical database registry report (2018). Chinese J Pract Surg. 2019;39:54–59.
  • BaldwinCM, KeamSJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs. 2009;69:1373–1401. doi:10.2165/00003495-200969100-0000719583455